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Abstract
Background
An association between pneumococcal serotypes and mortality has been suggested. We
aimed to investigate this among individuals aged15 years with invasive pneumococcal
disease (IPD) in South Africa.
Methods
IPD cases were identified through national laboratory-based surveillance at 25 sites, pre-
pneumococcal conjugate vaccine (PCV) introduction, from 2003–2008. We assessed the
association between the 20 commonest serotypes and in-hospital mortality using logistic
regression with serotype 4 (the third commonest serotype with intermediate case-fatality
ratio (CFR)) as referent.
Results
Among 3953 IPD cases, CFR was 55% (641/1166) for meningitis and 23% (576/2484) for
bacteremia (p<0.001). Serotype 19F had the highest CFR (48%, 100/207), followed by
serotype 23F (39%, 99/252) and serotype 1 (38%, 246/651). On multivariable analysis, fac-
tors independently associated with mortality included serotype 1 (OR 1.9, 95%CI 1.1–3.5)
and 19F (OR 2.9, 95%CI 1.4–6.1) vs. serotype 4; increasing age (25–44 years, OR 1.8,
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95%CI 1.0–3.0; 45–64 years, OR 3.6, 95%CI 2.0–6.4;65 years, OR 5.2, 95%CI 1.9–14.1;
vs. 15–24 years); meningitis (OR 4.1, 95%CI 3.0–5.6) vs. bacteremic pneumonia; and HIV
infection (OR1.7, 95%CI 1.0–2.8). On stratified multivariate analysis, serotype 19F was
associated with increased mortality amongst bacteremic pneumococcal pneumonia cases,
while no serotype was associated with increased mortality in meningitis cases.
Conclusion
Mortality was increased in HIV-infected individuals, which may be reduced by increased
antiretroviral therapy availability. Serotypes associated with increased mortality are
included in the 10-and-13-valent PCV and may become less common in adults due to indi-
rect effects following routine infant immunization.
Introduction
Streptococcus pneumoniae is a common cause of pneumonia, meningitis and septicemia and is
associated with substantial morbidity and mortality worldwide[1, 2]. Since the introduction of
pneumococcal conjugate vaccines (PCVs), a decline in the incidence of vaccine-serotype inva-
sive pneumococcal disease (IPD) has been observed in vaccinated children and unvaccinated
adults (through herd effect) in areas where the vaccine is widely used[3]. A significant burden
of IPD, however, exists worldwide due to serotypes that are not included in PCV, which has
increased in children and adults since the introduction of PCV into childhood immunization
programs[4].
Incidence, severity and mortality of IPD are influenced by host- and organism-related fac-
tors. The host-related factors include extremes of age, underlying chronic illness, immunosup-
pression and access to antibiotic treatment[5–8]. Pathogen-related factors include the
polysaccharide capsule which is the serotype determinant[9, 10]. Previous studies have shown
an association between pneumococcal serotypes and mortality in adults[11, 12]. These associa-
tions could differ in a middle-income country, such as South Africa, where there is a high HIV
prevalence (19% in adults aged 15–49 years in 2012)[13, 14] and a greater diversity of serotypes
associated with IPD[15]. In addition, few studies have examined the association between sero-
types and mortality in the absence of potential effects of pneumococcal vaccination and none
have examined the association between serotype and mortality separately in HIV-infected and
HIV-uninfected individuals[12].
We aimed to determine the association between pneumococcal serotype and in-hospital
mortality among patients aged15 years with IPD in South Africa during the period 2003–
2008, prior to the introduction of PCV in the routine immunization program.
Methods
Surveillance for IPD
From 2003, national, active, population-based, laboratory-based surveillance for IPD was con-
ducted through the GERMS-SA programme [16]. Reports of laboratory-confirmed IPD,
including demographic details as well as date of specimen, and source of isolate together with
isolates were sent to the National Institute for Communicable Diseases (NICD) in Johannes-
burg from>130 laboratories nationally. We conducted annual laboratory audits of all public-
sector laboratories in 8 provinces annually using DisaLab Laboratory Information
Pneumococcal mortality, South Africa
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Management System. We included cases identified by audit. At 25 sentinel enhanced surveil-
lance hospitals in all nine provinces we collected additional information from patient inter-
views including HIV serological status, admission date, discharge diagnosis and outcome.
Cases were defined as patients15 years of age with S. pneumoniae cultured from normally
sterile site specimens (e.g., cerebrospinal fluid [CSF], blood, pleural, peritoneal or joint fluid)
from January 2003 through December 2008. We excluded repeat isolates from the same indi-
vidual within 21 days of the initial positive culture. We defined specimen source using a hierar-
chical definition, as follows: CSF specimen regardless of other specimens; blood specimen
regardless of other specimens (excluding CSF); and other e.g., pleural fluid, joint fluid etc. with-
out CSF or blood. We only obtained information on clinical syndrome for enhanced surveil-
lance sites and we defined clinical syndrome using a hierarchical definition, as follows:
meningitis if a clinical diagnosis of meningitis was noted in the medical records or the pneumo-
coccus was isolated from CSF; bacteremic pneumonia if the clinical diagnosis of pneumonia
was noted in the medical records and the pneumococcus was isolated from blood culture; other
(including any diagnoses not including the preceding two, including bacteremia without any
localising site and localized pneumonia with pneumococcus isolated from other sterile sites
only). We defined predisposing conditions other than HIV infection as follows: asplenia, sickle
cell anemia; chronic illnesses including lung, liver, renal, cardiac disease and diabetes; other
immunocompromising conditions including malignancy, primary immunodeficiency, immu-
notherapy and organ transplant; as well as other Advisory Committee on Immunization Prac-
tices [17] risk factors including head injury with CSF leak, alcohol and smoking. Disease
severity was measured using the Pitt bacteremia score, which is a composite severity score
including patient temperature, presence of hypotension, receipt of mechanical ventilation, car-
diac arrest and mental status[18, 19]. We defined acute severe illness as a Pitt bacteremia score
of4 at the time of specimen collection. Provinces were grouped into 3 categories based on
poverty rates (low, intermediate and high) determined by the findings of the living conditions
survey conducted by Statistics South Africa in 2008–2009[20].
Serotyping and susceptibility testing
The Quellung reaction using specific antisera (Statens Serum Institut, Copenhagen, Denmark)
was used for pneumococcal serotyping. We separately distinguished serotypes 6A, B, C and D
for the whole study period, although serotypes 6C and 6D were identified from<1% of cases
[21]. Isolates were screened for penicillin resistance using oxacillin disc diffusion (Mast Diag-
nostics, Merseyside, United Kingdom) [22] and minimum inhibitory concentrations (MICs) of
the potentially resistant isolates were determined using agar dilution or Etest1 (AB-Biodisk,
Solna, Sweden). We interpreted results as non-susceptible (intermediately resistant and resis-
tant) or susceptible using 2008 Clinical and Laboratory Standards Institute (CLSI) definitions
[22]. We considered isolates with MICs0.12mg/L to be non-susceptible to penicillin at using
the oral penicillin breakpoint. We defined multi-drug resistance as non-susceptibility to any
three or more different antibiotic classes, according to the 2009 definitions of the CLSI. [22]
For determination of appropriate antibiotic prescription, data on the antibiotics used for
patient management was compared with the recommended antibiotic guidelines to determine
whether the appropriate antibiotic was administered to the patient[23].
Statistical analysis
The study population included all patients with IPD aged15 years from 2003 to 2008. Because
our main focus was on the association between serotypes and in-hospital outcome, we included
only patients with known in-hospital outcome at enhanced surveillance sites and presenting
Pneumococcal mortality, South Africa
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with one of the 20 most common serotypes, to allow sufficient numbers in each group for com-
parison. We a priori included the serotypes in PCV-13 i.e 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,
19A, 19F and 23F. In addition we included serotypes 8, 12F, 16, 9N, 22F, 25 and 13.
Mortality was defined as death in hospital and within 30 days of the IPD episode, to avoid
inclusion of deaths unrelated to IPD. To explore possible bias introduced by including only
patients presenting to enhanced surveillance sites we compared the characteristics of patients
presenting to enhanced and non-enhanced sites using logistic regression.
To assess differences between serotypes we evaluated the association of age (age group 15–
24 years, 25–44 years, 45–64 years,65 years), clinical syndrome (meningitis, bacteremic
pneumonia and other IPD), HIV co-infection and in-hospital mortality for each serotype com-
pared to serotype 4. We chose serotype 4 as the referent as it was the third most common sero-
type (289/3953, 7%) identified and we wanted to use a serotype with an intermediate CFR
(29%) as referent to allow for identification of serotypes with particularly high or low CFR. We
used univariate multinomial regression models, generating a separate estimate of effect for
each predictor on each outcome relative to the base level. The effect measures are the ratios of
two relative risks (relative risk ratios) with each relative risk describing the probability of the
outcome in the category of interest relative to the baseline category[24].
To determine factors associated with in-hospital mortality, we used logistic regression. We
assessed all variables that were significant at p<0.2 on univariate analysis, and eliminated from
the model non-significant factors (p0.05) with stepwise backward selection. Patients with
missing data for included variables were excluded from the model. Serotype was retained in all
multivariate models a priori because it was the main variable of interest and clinical syndrome
because it is an important potential confounder. For the analysis of factors associated with
mortality in HIV-infected individuals CD4 + T cell count was not included in the multivariable
model because of a large amount (>40%) of missing data, however, CD4+ T cell count was not
associated with serotype. All analyses were done using Stata Version 13 (StataCorp Limited).
Two-sided p values<0.05 were considered significant. We performed stratified analyses for
meningitis and bacteremic pneumonia separately and HIV-infected and—uninfected individu-
als separately, to explore whether the association between serotype and mortality varied within
these subgroups. For each analysis, we used all available case information. Variables were
binary (yes/no), defined as the presence or absence of the attribute excluding missing data, or
categorical variables in multiple levels. We performed a sensitivity analysis restricting the study
population to individuals aged18 years.
Ethics Procedures
The national surveillance programme includes national laboratory-based surveillance where
demographic data and isolates are sent to NICD routinely without requiring patient consent as
part of the NICD’s national public health surveillance responsibility. In addition, at sentinel
enhanced surveillance sites, additional data is obtained from patient interviews, only from indi-
viduals who provide written informed consent. For participants under the age of 18, written
informed consent was obtained from parents or legal guardians. The surveillance protocol (lab-
oratory-based and enhanced surveillance) was approved by the University of the Witwaters-
rand Human Research Ethics Committee (Medical) (M0801117) and other relevant
institutional ethics committees.
Results
From 2003–2008, 27,632 patients with IPD were reported to the GERMS-SA surveillance pro-
gram (Fig 1). Among 26,278 (95%) with known age, 15,105 (57%) were aged15 years.
Pneumococcal mortality, South Africa
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Fig 1. Flow diagram of patients with invasive pneumococcal disease (IPD) in South Africa, 2003–2008 and included in the analysis. *Pneumococci
that did not have a capsule and could not be serotyped. **Isolates from patients that were simultaneously infected with two strains of pneumococci with
different serotypes.
doi:10.1371/journal.pone.0140185.g001
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Among these, 49% (7329) were from enhanced sites and 82% (6021) of these had known in-
hospital outcome. Of patients with known outcomes, 4697 (78%) had viable, serotypeable iso-
lates from a single IPD episode and 3953 (84%) of these were due to the 20 most frequent sero-
types including PCV-13 vaccine serotypes. Data on clinical diagnosis was available for 99%
(3923/3953) of individuals.
The overall case-fatality ratio (CFR) was 34% (1333/3953): 55% (641/1166) amongst
patients with meningitis, 23% (576/2484) in patients with bacteremic pneumonia and 36% (98/
273) in patients with other IPD. Serotype 1 was the commonest serotype identified (651/3953,
16%), followed by serotype 19A (443/3953, 11%), serotype 4 (289/3953, 7%) and serotype 3
(284/3953, 7%). The majority of patients (64%, 2527/3953) were aged 25–44 years, 54% (2146/
3952) were female and of those with known status, 89% (2309/2580) were HIV infected.
Comparing patients at enhanced to non-enhanced surveillance sites, on multivariable analy-
sis, patients from enhanced sites were more likely to come from an intermediate poverty level
province (odds ratio [OR] 1.3, 95% confidence interval [CI] 1.2-1.5) and less likely to come
from a high poverty level province (OR 0.5, 95% CI 0.4-0.6)(vs low poverty province), more
likely to be of non-black race (OR 3.3, 95% CI 2.5-4.2), more likely to have blood (OR 2.4, 95%
CI 2.1–2.7) or other (OR 1.3, 95% CI 1.0–1.5) specimen type (vs CSF) and more likely to have
disease due to serotype 9N (OR 1.6, 95% CI 1.1–2.5) or 22F (OR 22.1, 95% CI 5.3–91.6)(vs
serotype 4) (Table 1).
Univariate multinomial analysis of the 20 commonest serotypes by age
group, syndrome, in-hospital outcome and HIV co-infection
Analyzing the 20 most common serotypes, using multinomial regression, comparing the age
distribution of all other serotypes to the age distribution of serotype 4 (25–44 years as the refer-
ent group), serotype 3 was significantly more likely to be identified from patients 45–64 years
of age (relative risk ratio [RRR] 1.9, 95% CI 1.2–2.8), serotype 1 was significantly more likely to
be isolated from patients 15–24 years of age (RRR 1.8. 95% CI 1.2–2.8) and serotype 19F was
significantly more likely to be isolated from patients 45–64 years of age (RRR 1.6 95% CI 1.1–2.
6) (Fig 2).
Compared to serotype 4, serotypes 12F (RRR 3.1, 95% CI 1.1–9.3) and 9V (RRR 12.0, 95%
CI 1.6–90.3) caused significantly more disease in HIV-infected individuals, whereas serotype 1
(RRR 0.5, 95% CI 0.3–0.8) was significantly less likely in HIV-infected patients (Fig 3).
Serotypes 6A (RRR 1.5, 95% CI 1.0–2.1), 23F (RRR 1.6, 95% CI 1.1–2.3), 12F (RRR 1.8, 95%
CI 1.2–2.7) and 18C (RRR 2.2, 95% CI 1.2–3.8) were more likely to present as meningitis, while
serotypes 19A (RRR 2.2, 95% CI 1.6–3.2), 3 (RRR 3.3, 95% CI 2.1–5.1), 14 (RRR 2.1, 95% CI
1.4–3.2), 9N (RRR 2.2, 95% CI 1.2–4.0), 7F (RRR 2.1, 95% CI 1.1–4.1), 25 (RRR 2.6, 95% CI
1.3–5.3) and 5 (RRR 6.3, 95% CI 2.2–18.0) were more likely to present as bacteremia when
compared to serotype 4 (Fig 4).
In addition, serotypes 1 (RRR 1.5, 95% CI 1.1–2.0), 23F (RRR 1.6, 95% CI 1.1–2.3) and 19F
(RRR 2.3, 95% CI 1.6–3.4) were significantly more likely to cause death compared to serotype
4. Serotype 25 (RRR 0.4, 95% CI 0.2–0.9) was associated with a lower probability of death com-
pared to serotype 4 (Fig 5).
Factors associated with in-hospital mortality overall
Among all patients with IPD aged15 years, on multivariable analysis, compared to serotype
4, infection with serotype 1 (OR 1.9, 95% CI 1.1–3.5), 14 (OR 2.1, 95% CI 1.0–4.2) and 19F
(OR 2.9, 95% CI 1.4–6.1) was associated with increased in-hospital mortality (Table 2). Addi-
tional factors associated with in-hospital mortality on multivariable analysis controlling for
Pneumococcal mortality, South Africa
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province were increasing age (25–44 years OR 1.8 95% CI 1.0–3.0; 45–64 years OR 3.6, 95% CI
2.0–6.4;65 years OR 5.2, 95% CI 1.9–14.1 vs 15–24 years), meningitis (vs bacteremia) (OR
4.1, 95% CI 3.0–5.6), history of antibiotic use in the two months preceding the IPD episode
(OR 3.9 95% CI 2.5–6.2), inappropriate antibiotic prescription (OR 2.4, 95% CI 1.7–3.2) and
being HIV infected (OR 1.7, 95% CI 1.0–2.8).
Factors associated with in-hospital mortality stratified by clinical
syndrome
Among patients with bacteremic pneumonia, on multivariable analysis, compared to serotype
4, infection with serotype 14 (OR 2.2, 95% CI 1.1–4.7) and 19F (OR 3.5, 95% CI 1.6–8.0) was
associated with increased in-hospital mortality (Table 3). Additional factors associated with in-
Table 1. Comparison of demographic and clinical characteristics of patients aged15 years with invasive pneumococcal disease (IPD) in South
Africa fromGERMS-SA enhanced and non-enhanced sites, 2003–2008.
Variable Enhanced sites Non-enhanced sites Univariate analysis Multivariable analysis
n (%) n (%) OR (95% CI) p OR (95% CI) p
Province* Low poverty 5377/7329 (73) 4601/7776 (59) Reference Reference Reference Reference
Intermediate poverty 1431/7329 (20) 1539/7776 (20) 0.8 (0.7–0.9) <0.001 1.3 (1.2–1.5) <0.001
High poverty 521/7329 (7) 1636/7776 (21) 0.27 (0.3–0.3) <0.001 0.5 (0.4–0.6) <0.001
Race Non-black 539/6779 (8) 93/4242 (2) 3.9 (3.1–4.8) <0.001 3.3 (2.5–4.2) <0.001
Specimen CSF 1727/7329 (24) 3398/7776 (44) Reference Reference Reference Reference
Blood 4955/7329 (67) 3161/7776 (41) 3.1 (2.9–3.3) <0.001 2.4 (2.1–2.7) <0.001
Other 647/7329 (9) 1217/7776 (16) 1.1(0.9–1.2) 0.021 1.3 (1.0–1.5) 0.007
Serotype 1 463/4528 (17) 920/4434 (21) 0.9 (0.8–1.1) 0.532 0.9 (0.8–1.2) 0.541
19A 486/4528 (11) 401/4434 (9) 1.4 (1.1–1.7) 0.002 1.06 (0.8–1.3) 0.332
4 323/4528 (7) 368/4434 (8) Reference Reference Reference Reference
3 323/4528 (7) 251/4434 (6) 1.5 (1.2–1.8) 0.001 1.1 (0.8–1.4) 0.559
6A 300/4528 (7) 321/4434 (7) 1.1 (0.9–1.3) 0.751 1.0 (0.8–1.3) 0.515
14 284/4528 (6) 282/4434 (6) 1.1 (0.9–1.4) 0.374 1.05 (0.7–1.2) 0.516
23F 301/4528 (6) 285/4434 (7) 1.2 (0.9–1.4) 0.761 1.3 (1.0–1.7) 0.031
8 230/4528 (5) 243/4434 (5) 1.1 (0.9–1.4) 0.968 1.0 (0.7–1.3) 0.933
19F 240/4528 (5) 200/4434 (5) 1.4 (1.1–1.7) 0.011 1.3 (0.9–1.7) 0.079
6B 230/4528 (5) 234/4434 (6) 1.1 (0.8–1.3) 0.571 1.0 (0.8–1.3) 0.702
12F 215/4528 (5) 257/4434 (6) 1.0 (0.8–1.2) 0.203 0.9 (0.7–1.3) 0.858
9V 163/4528 (4) 157/4434 (4) 1.18 (0.9–1.5) 0.708 1.3 (0.9–1.7) 0.431
16 116/4528 (3) 108/4434 (2) 1.2 (0.9–1.6) 0.588 1.1 (0.7–1.6) 0.583
9N 101/4528 (2) 68/4434 (2) 1.7 (1.2–2.4) 0.003 1.6 (1.1–2.5) 0.029
7F 80/4528 (2) 67/4434 (2) 1.4 (0.9–2.0) 0.067 1.1 (0.7–1.6) 0.462
18C 81/4528 (2) 89/4434 (2) 1.0 (0.7–1.4) 0.583 1.1 (0.7–1.6) 0.820
25 74/4528 (2) 52/4434 (1) 1.6 (1.1–2.4) 0.014 1.1 (0.7–1.7) 0.401
22F 74/4528 (2) 2/4434 (0.1) 42.2 (10.3–173.1) <0.001 22.1 (5.3–91.6) <0.001
13 78/4528 (2) 65/4434 (1) 1.4 (1.0–2.0) 0.173 1.4 (0.9–2.1) 0.151
5 64/4528 (1) 64/4434 (1) 1.1 (0.8–1.6) 0.944 0.9 (0.6–1.5) 0.656
N-number, OR—Odds ratio, CI—conﬁdence interval, CSF- cerebrospinal ﬂuid. Only factors statistically signiﬁcant on univariate analysis are included in
the table. Additional variables evaluated were age group and gender.
*The low poverty rate group consisted of Gauteng and Western Cape. The intermediate poverty rate group consisted of KwaZulu-Natal, Free State,
Northern Cape and North West. The high poverty rate group consisted of Eastern Cape, Mpumalanga and Limpopo.
doi:10.1371/journal.pone.0140185.t001
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hospital mortality on multivariable analysis among patients with bacteremic pneumonia were
increasing age group (25–44 years OR 2.7 95% CI 1.5–5.0; 45–64 years OR 6.2, 95% CI 3.1–
12.7;65 years OR 11.7, 95% CI 3.4–40.4 vs 15–24 years), history of antibiotic use in the 2
months preceding the IPD episode (OR 2.3 95% CI 1.4–3.9) and inappropriate antibiotic pre-
scription (OR 2.8, 95% CI 2.0–3.8).
Among patients with meningitis, on multivariable analysis, compared to serotype 4, infec-
tion with serotype 16 (OR 0.2, 95% CI 0.03–0.9) was associated with lower in-hospital mortal-
ity (Table 3). Additional factors associated with in-hospital mortality on multivariable analysis
among patients with meningitis were age group 45–64 years (OR 7.1, 95% CI 2.8–18.2 vs 15–
24 years), Pitt bacteremia score4 (OR 2.4, 95% CI 1.4–4.1), history of antibiotic use in the 2
months preceding the IPD episode (OR 5.0 95% CI 2.0–12.5) and being HIV infected (OR 6.1,
95% CI 2.1–17.6).
Factors associated with in-hospital mortality stratified by HIV-infection
status
Amongst HIV-infected individuals, on multivariable analysis, compared to serotype 4, infec-
tion with serotype 19F (OR 2.6, 95% CI 1.2–5.7) was associated with increased in-hospital
Fig 2. Distribution of pneumococcal serotypes amongst patients aged15 years with invasive pneumococcal disease (IPD) in South Africa from
2003–2008, by age group. # Reference group. *Statistically significant at p<0.05.
doi:10.1371/journal.pone.0140185.g002
Pneumococcal mortality, South Africa
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mortality (Table 4). Additional factors associated with in-hospital mortality on multivariable
analysis among HIV-infected individuals included increasing age group (25–44 years OR 1.9,
95% CI 1.1–3.4; 45–64 years OR 3.6, 95% CI 1.9–68;65 years OR 6.9, 95% CI 1.8–25.9 vs 15–
24 years), history of antibiotic use in the 2 months preceding the IPD episode (OR 4.3 95% CI
2.7–7.1), inappropriate antibiotic prescription (OR 2.5, 95% CI 1.8–3.4) and meningitis (OR
4.6 95% CI 3.3–6.0 vs bacteremia). CD4+ T cell count was available for only 1315 of 2309
(57%) HIV-infected individuals, of whom 1031 (45%) were<200 cells/mm3. CFRs were higher
in patients with CD4+ T cell count<200 (297/1031, 29%) compared to those with CD4+ T cell
count200 cells/mm3 (38/284, 13%, p<0.001). CD4 + T cell count<200 cells/mm3 was not
associated with serotype (p = 0.754). Amongst 1744 HIV-infected individuals with available
data, 10% (n = 178) reported receiving anti-retroviral therapy (ART). CFRs were similar in
individuals receiving (47/178, 26%) and not receiving (354/1566, 23%) ART (p = 0.254).
Amongst HIV-uninfected individuals, on multivariable analysis, compared to serotype 4,
infection with serotype 12F (OR 23.9, 95% CI 1.2–176.5), serotype 16 (OR 28.3 95% CI 1.9–
414.9) and serotype 9N (OR 16.3 95% CI 1.1–255.8) was associated with increased in-hospital
mortality. Additional factors associated with in-hospital mortality among HIV-uninfected
individuals included increasing age group (25–44 years OR 4.7, 95% CI 1.4–16.4; 45–64 years
Fig 3. Distribution of pneumococcal serotypes amongst patients aged15 years with invasive pneumococcal disease (IPD) in South Africa from
2003–2008, by HIV-infection status. # Reference group. *Statistically significant at p<0.05.
doi:10.1371/journal.pone.0140185.g003
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OR 11.8, 95% CI 3.1–44.6;65 years OR 12.9, 95% CI 2.6–64.6 vs 15–24 years) and elevated
Pitt bacteraemia score (OR 3.9, 95% CI 1.8–8.6).
Individuals aged 15–17 years made up only 1% (51/3953) of included individuals. Sensitivity
analysis excluding individuals aged 15–17 years did not change any of the study conclusions
(data not shown).
Discussion
We have described extremely high in-hospital mortality in individuals aged15 years with
IPD in South Africa, particularly for meningitis, where CFRs exceed 50%. Individual serotypes
(1, 14 and 19F) were associated with increased mortality, even after controlling for confound-
ers, suggesting pneumococcal capsule characteristics may be related to virulence. Other impor-
tant factors associated with increased in-hospital mortality were increasing age and underlying
HIV infection. All of the serotypes associated with increased mortality are included in PCV-10
and -13 and use of these vaccines in infants has reduced the burden of these serotypes in chil-
dren as well as among adults through a herd effect [25, 26].
As has been described in other studies, serotypes causing IPD varied by age group, HIV sta-
tus and clinical syndrome, all important factors potentially associated with mortality[27, 28].
For this reason, it is important to control for potential confounders when assessing the
Fig 4. Distribution of pneumococcal serotypes amongst patients aged15 years with invasive pneumococcal disease (IPD) in South Africa from
2003–2008, by clinical syndrome. # Reference group. *Statistically significant at p<0.05
doi:10.1371/journal.pone.0140185.g004
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association between serotype and mortality. We found serotypes 1, 14 and 19F to be signifi-
cantly associated with mortality, and particularly when presenting with bacteremia. Previous
studies have found serotype 19F to be associated with increased CFR [11, 12, 29]. Serotype 14
was also associated with increased mortality in the current study, which has not been previ-
ously described. Serotype 1 was the commonest serotype in our study population and we found
it to be associated with increased CFR. Some studies have found serotype 1 to be associated
with decreased risk of death [11, 12], although increased CFR as found in our study has been
observed previously [30]. Previous studies have suggested that serotypes with increased relative
risks of death had a higher carriage prevalence and low invasiveness[11]. Serotype 1 has been
described as among the more invasive serotypes and serotype 19F among the less invasive sero-
types [12, 29, 31, 32].
Differences in the association between serotype and mortality in our study compared to pre-
vious studies could be partly as a result of the high HIV-prevalence (89% HIV prevalence
amongst included IPD cases) in the population studied. Interestingly, when stratified by HIV-
infection status, different serotypes were found to be associated with increased mortality in
HIV-infected (serotype 19F) and HIV-uninfected (serotypes 12F, 16 and 9N) individuals. Sero-
type 1 was not found to be independently associated with increased mortality in either the
HIV-infected or -uninfected group, although CFRs were elevated for this serotype in both
HIV-infected and—uninfected individuals. Other factors associated with mortality also
Fig 5. Distribution of pneumococcal serotypes amongst patients aged15 years with invasive pneumococcal disease (IPD) in South Africa from
2003–2008, by in-hospital outcome. # Reference group. *Statistically significant at p<0.05
doi:10.1371/journal.pone.0140185.g005
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Table 2. Univariate andmultivariable analysis of factors associated with mortality amongst patients aged15 years with invasive pneumococcal
disease (IPD) in South Africa, 2003–2008.
Risk factor Percent of all enrolled cases Case-fatality ratio Univariate analysis Multivariable analysis
n/N (%) n/N (%) OR (95% CI) p OR (95% CI) p
Age group (years) 15–24 406/3953 (10) 92/406 (23) Reference Reference Reference Reference
25–44 2527/3953 (64) 793/2527 (31) 1.6 (1.2–2.0) <0.001 1.8 (1.0–3.0) 0.037
45–64 810/3953 (21) 348/810 (43) 2.6 (2.0–3.4) <0.001 3.6 (2.0–6.4) <0.001
65 210/3953 (5) 100/210 (48) 3.1 (2.2–4.4) <0.001 5.2 (1. 9–14.1) 0.001
Province poverty level* Low 2934/3953 (74) 915/2934 (31) Reference Reference Reference Reference
Intermediate 780/3953 (20) 301/780 (39) 1.4 (1.2–1.6) <0.001 1.6 (1.2–2.4) 0.005
High 239/3953 (6) 117/239 (49) 2.1 (1.6–2.8) <0.001 1.7 (1.0–3.0) 0.042
Disease syndrome Meningitis 1166/3923 (30) 641/1166 (55) 4.0 (1.2–2.2) <0.001 4.1 (3.0–5.6) <0.001
Bacteremic pneumonia 2484/3923 (63) 576/2484 (23) Reference Reference Reference Reference
Other 273/3923(7) 98/273 (36) 1.9 (0.3–0.5) <0.001 1.6 (0.9–2.9) 0.104
Pitt bacteremia score <4 2993/3953 (76) 864/2993 (29) Reference Reference
4 960/3953 (24) 469/960 (49) 2.4 (2.0–2.7) <0.001
Prior antibiotic use (24 hours) Yes 96/2968 (3) 41/96 (43) 2.1 (1.4–3.1) 0.001
No 2872/2968 (97) 759/2872 (26) Reference Reference
Prior antibiotic use (2 months) Yes 149/2402 (6) 59/149 (40) 2.6 (1.8–3.6) <0.001 3.9 (2.5–6.2) <0.001
No 2253/2402 (94) 458/2253 (20) Reference Reference Reference Reference
Appropriate antibiotic prescription Yes 3005/3923 (77) 900/3005 (30) Reference Reference Reference Reference
No 918/3923 (23) 415/918 (45) 1.9 (1.7–2.3) <0.001 2.4 (1.7–3.2) <0.001
HIV status Positive 2309/2580 (89) 687/2309 (30) 1.5(1.1–2.0) 0.013 1.7 (1.0–2.8) 0.035
Negative 271/2580 (11) 61/271 (23) Reference Reference Reference Reference
Nosocomial infection Yes 168/3953 (4) 73/168 (44) 1.5 (1.1–2.1) 0.007
No 3785/3953(96) 1260/3785 (33) Reference Reference
Multi-drug resistant Yes 609/3953 (15) 230/609 (38) 1.2 (1.0–1.5) 0.022
No 3344 (85) 1103/3344(33) Reference Reference
Serotype 1 651/3953 (17) 246/651 (38) 1.5 (1.1–2.0) 0.007 1.9 (1.1–3.5) 0.034
19A 443/3953 (11) 151/443 (34) 1.3 (0.9–1.8) 0.128 1.8 (0.9–3.4) 0.075
4 289/3953 (7) 83/289 (29) Reference Reference Reference Reference
3 284/3953 (7) 98/284 (35) 1.3 (0.9–1.9) 0.137 1.2 (0.5–2.5) 0.727
6A 269/3953 (7) 89/269 (33) 1.2 (0.9–1.8) 0.265 0.8 (0.4–1.6) 0.501
14 253/3953 (6) 83/253 (33) 1.2 (0.8–1.8) 0.303 2.1 (1.0–4.2) 0.049
23F 252/3953 (6) 99/252 (39) 1.6 (1.1–2.3) 0.010 1.9 (0.9–3.8) 0.073
8 209/3953 (5) 52/209 (25) 0.8 (0.6–1.2) 0.342 1.2 (0.5–2.7) 0.637
19F 207/3953 (5) 100/207 (48) 2.3 (1.6–3.4) <0.001 2.9 (1.4–6.1) 0.005
6B 202/3953 (5) 64/202 (32) 1.2 (0.8–1.7) 0.481 1.4 (0.7–2.8) 0.428
12F 175/3953 (4) 60/175 (34) 1.3 (0.9–1.9) 0.209 1.2 (0.5–2.9) 0.757
9V 140/3953 (4) 45/140 (32) 1.18 (0.8–1.8) 0.468 1.8 (0.8–4.4) 0.187
16 103/3953 (3) 34/103 (33) 1.22 (0.8–2.0) 0.414 0.4 (0.1–1.5) 0.201
9N 89/3953 (2) 26/89 (29) 1.0 (0.6–1.7) 0.928 0.9 (0.3–3.0) 0.888
7F 73/3953 (2) 15/73 (21) 0.6 (0.3–1.2) 0.163 1.0 (0.3–3.0) 0.965
18C 68/3953 (2) 24/68 (35) 1.4 (0.8–2.4) 0.288 1.3 (0.4–4.1) 0.611
25 66/3953 (2) 10/66 (15) 0.4 (0.2–0.9) 0.027 0.8 (0.2–3.1) 0.701
22F 64/3953 (2) 22/64 (34) 1.3 (0.7–2.3) 0.371 1.3 (0.4–4.7) 0.674
13 63/3953 (2) 21/63 (33) 1.2 (0.7–2.2) 0.468 2.0 (0.7–5.8) 0.234
5 53/3953 (1) 11/53 (21) 0.7 (0.3–1.3) 0.235 0.3 (0.0–3.0) 0.291
N-number, OR—Odds ratio, CI—conﬁdence interval, HIV—Human immunodeﬁciency virus, PCV- pneumococcal conjugate vaccine. Only factors
statistically signiﬁcant on univariate analysis are included in the table. Additional variables evaluated were gender, race, presence of underlying medical
conditions other than HIV and penicillin non-susceptibility.
*The low poverty rate group consisted of Gauteng and Western Cape. The intermediate poverty rate group consisted of KwaZulu-Natal, Free State,
Northern Cape and North West. The high poverty rate group consisted of Eastern Cape, Mpumalanga and Limpopo.
doi:10.1371/journal.pone.0140185.t002
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Table 3. Multivariable analysis of factors associated with in-hospital mortality amongst patients aged15 years with invasive pneumococcal dis-
ease (IPD) in South Africa from 2003–2008, with bacteremic pneumonia andmeningitis separately.
Risk factor Bacteremic pneumonia Meningitis
Case-fatality
ratio n/N (%)
Adjusted odds ratio (95%
conﬁdence interval)
p Case-fatality
ratio n/N (%)
Adjusted odds ratio (95%
conﬁdence interval)
p
Age group (years) 15–24 23/225 (10) Reference Reference 54/141 (38) Reference Reference
25–44 320/1582 (20) 2.7 (1.5–5.0) 0.009 421/770 (55) 1.8 (0.9–4.1) 0.110
45–64 175/527 (33) 6.2 (3.1–12.7) <0.001 145/226 (64) 7.1 (2.8–18.2) <0.001
65 58/150 (39) 11.7 (3.4–40.4) <0.001 21/29 (72) 8.3 (0.6–108.4) 0.106
Pitt bacteremia
score
<4 401/807 (50) Reference
4 240/359 (67) 2.4 (1.4–4.1) <0.001
Prior antibiotic use
(2 months)
Yes 27/95 (28) 2.3 (1.4–3.9) 0.001 22/34 (65) 5.0 (2.0–12.5) <0.001
No 200/1519 (13) Reference Reference 220/577 (38) Reference Reference
Appropriate
antibiotic
prescription
Yes 397/1976 (20) Reference Reference
No 179/508 (35) 2.8 (2.0–3.8) <0.001
HIV status Positive 336/634 (53) 6.1 (2.1–17.6) 0.001
Negative 19/73 (26) Reference Reference
Serotype 1 60/363 (17) 1.2 (0.6–2.4) 0.709 174/243 (72) 2.0 (0.8–4.6) 0.149
19A 93/342 (27) 1.5 (0.8–3.1) 0.251 52/82 (63) 1.1 (0.4–3.2) 0.811
4 29/177 (16) Reference Reference 51/95 (54) Reference Reference
3 69/216 (32) 2.0 (1.0–4.2) 0.061 13/35 (37) 0.2 (0.02–1.5) 0.103
6A 31/138 (22) 0.7 (1.3–2.0) 0.517 50/109 (46) 0.5 (0.2–1.2) 0.125
14 55/184 (30) 2.2 (1.1–4.7) 0.039 20/47 (43) 0.5 (0.1–1.8) 0.267
23F 27/124 (22) 1.5 (0.6–3.7) 0.352 59/106 (56) 0.9 (0.2–2.9) 0.765
8 14/138 (10) 0.8 (0.3–2.0) 0.649 32/528 (55) 0.9 (0.3–3.1) 0.851
19F 51/116 (44) 3.5 (1.6–8.0) 0.002 35/64 (55) 0.7 (0.2–2.5) 0.567
6B 22/123 (18) 1.0 (0.4–2.5) 0.954 38/67 (57) 1.0 (0.4–3.0) 0.975
12F 16/79 (20) 1.2 (0.4–3.3) 0.778 38/75 (51) 0.7 (0.2–2.6) 0.598
9V 23/93 (25) 2.0 (0.8–5.2) 0.153 19/36 (53) 0.2 (0.01–1.4) 0.230
16 19/68 (28) 0.6 (0.2–2.4) 0.508 12/30 (40) 0.2 (0.03–0.9) 0.040
9N 17/66 (26) 1.1 (0.4–3.5) 0.863 6/16 (38) 0.4 (0.1–4.0) 0.444
7F 10/56 (18) 0.9 (0.2–3.5) 0.868 3/14 (21) 0.4 (0.1–2.1) 0.271
18C 6/26 (23) 1.5 (0.4–85.8) 0.583 10/30 (47) 1.4 (0.3–7.0) 0.716
25 7/54 (13) 0.5 (0.1–2.6) 0.440 3/11 (27) 0.2 (0.01–2.0) 0.155
22F 11/43 (26) 1.6 (0.4–5.6) 0.498 9/17 (53) 0.5 (0.1–3.0) 0.409
13 7/31 (23) 1.6 (0.5–5.7) 0.435 11/27 (41) 1.1 (0.3–5.2) 0.851
5 9/47 (19) 0.7 (0.2–3.6) 0.703 2/4 (50) 0.8 (0.02–36.0) 0.923
N-number, OR—Odds ratio, CI—conﬁdence interval, HIV—Human immunodeﬁciency virus. Serotype was retained in the multivariate models a priori
because it was the main variable of interest. Only factors statistically signiﬁcant on multivariable analysis for the syndrome of interest are presented in the
table. Additional factors evaluated for patients with bacteremic pneumonia were: (a) factors non-signiﬁcant on univariate analysis: race, gender, province
poverty level, appropriate antibiotic prescription (b) factors signiﬁcant on univariate analysis but not on multivariable analysis: underlying medical
conditions other than HIV, serotype, receipt of antibiotics in the 24 hours preceding culture, nosocomial infection, penicillin non-susceptibility, multidrug
resistance. Additional factors evaluated for patients with meningitis were: (a) factors non-signiﬁcant on univariate analysis: gender, province poverty level,
receipt of antibiotics in the 24 hours preceding culture, appropriate antibiotic prescription, nosocomial infection, penicillin non-susceptibility, multidrug
resistance (b) factors signiﬁcant on univariate analysis but not on multivariable analysis: race, underlying medical conditions other than HIV, serotype.
doi:10.1371/journal.pone.0140185.t003
Pneumococcal mortality, South Africa
PLOS ONE | DOI:10.1371/journal.pone.0140185 October 13, 2015 13 / 19
Table 4. Multivariable analysis of factors associated with in-hospital mortality amongst patients aged15 years with invasive pneumococcal dis-
ease (IPD) in South Africa from 2003–2008, for HIV-infected and—uninfected patients separately.
Risk factor HIV-infected HIV-uninfected
Case-fatality
ratio n/N (%)
Adjusted odds ratio
(95% conﬁdence
interval)
p Case-fatality
ratio n/N (%)
Adjusted odds ratio
(95% conﬁdence
interval)
p
Age group (years) 15–24 48/210 (23) Reference 4/44 (9) Reference
25–44 482/1688 (29) 1.9 (1.1–3.4) 0.025 25/118 (21) 4.7 (1.4–16.4) 0.015
45–64 145/384 (38) 3.6 (1.9–6.8) <0.001 24/84 (29) 11.8 (3.1–44.6) <0.001
65 11/27 (41) 6.9 (1.8–25.9) 0.004 8/25 (32) 12.9 (2.6–64.6) 0.002
Race Black 55/214 (26) Reference
Other 6/56 (11) 0.2 (0.1–0.5) 0.002
Pitt bacteremia
score
<4 37/211 (18) Reference
4 24/60 (40) 3.9 (1.8–8.6) 0.001
Province poverty
level*
Low 517/1855 (28) Reference
Intermediate 129/357 (36) 1.9 (1.3–2.7) 0.001
High 41/97 (42) 1.9 (1.1–3.3) 0.025
Prior antibiotic use
(2 months)
Yes 43/95 (45) 4.3 (2.7–7.1) <0.001
No 232/1383 (17) Reference
Appropriate
antibiotic
prescription
Yes 469/1782 (26) 2.5 (1.8–3.4) <0.001
No 213/515 (41) Reference
Disease syndrome Meningitis 336/634 (53) 4.6 (3.3–6.0) <0.001 19/73 (26) 1.6 (0.7–3.7) 0.226
Bacteremic
pneumonia
317/1550 (20) Reference 34/170 (20) Reference
Other 29/113 (26) 1.6 (0.8–3.0) 0.001 7/27 (26) 1.7 (0.6–5.3) 0.349
Serotype 1 104/317 (33) 1.7 (0.9–3.2) 0.104 20/78 (26) 5.0 (0.6–44.6) 0.151
19A 91/283 (32) 1.7 (0.9–3.4) 0.098 5/22 (23) 6.2 (0.6–65.5) 0.132
4 45/178 (25) Reference 2/22 (9) Reference
3 30/149 (20) 0.8 (0.3–1.9) 0.480 7/24 (29) 7.2 (0.7–73.7) 0.095
6A 51/174 (29) 0.6 (0.3–1.3) 0.200 5/16 (32) 6.5 (0.6–72.1) 0.128
14 44/151 (29) 2.1 (1.0–4.4) 0.052 2/16 (13) 2.5 (0.2–34.4) 0.483
23F 69/164 (42) 1.6 (0.8–3.2) 0.898 3/11 (27) 7.9 (0.6–103.2) 0.116
8 23/112 (21) 1.1 (0.5–2.6) 0.726 4/21 (19) 3.5 (0.3–40.1) 0.317
19F 53/118 (45) 2.6 (1.2–5.7) 0.014 3/9 (33) 12.3 (0.9–162.2) 0.056
6B 36/126 (29) 1.2 (0.6–2.6) 0.994 1/13 (8) 2.4 (0.1–45.9) 0.561
12F 30/101 (30) 1.0 (0.5–1.9) 0.907 2/4 (50) 23.9 (1.2–476.5) 0.037
9V 30/97 (31) 1.7 (0.7–4.1) 0.257 0/1 (0) Omitted
16 16/63 (25) 0.3 (0.1–1.1) 0.060 3/7 (43) 28.3 (1.9–414.9) 0.015
9N 13/54 (24) 0.7 (0.2–2.7) 0.716 2/7 (29) 16.3 (1.1–255.8) 0.047
7F 12/49 (24) 0.9 (0.3–2.9) 0.300 0/4 (0) Omitted
18C 12/38 (32) 1.2 (0.4–3.7) 0.828 1/3 (33) 7.5 (0.3–198.6) 0.226
25 6/43 (14) 0.7 (0.2–2.9) 0.645 0/1 (0) Omitted
22F 10/38 (26) 1.3 (0.3–4.6) 0.736 0/2 (0) Omitted
13 9/29 (31) 2.2 (0.7–6.8) 0.785 1/5 (20) 2.6 (0.1–78.6) 0.581
5 3/25 (12) 0.2 (0.1–2.9) 0.267 0/5 (0) Omitted
N-number, OR—Odds ratio, CI—conﬁdence interval, HIV—Human immunodeﬁciency virus. Only factors statistically signiﬁcant on multivariable analysis
for the syndrome of interest are presented in the table. Serotype was retained in the multivariate models a priori because it was the main variable of
interest, and clinical diagnosis because it is an important potential confounder of the association between serotype and mortality.
doi:10.1371/journal.pone.0140185.t004
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differed between the two groups. In the HIV-infected subgroup, meningitis was associated
with almost five times increased odds of death, but mortality was not significantly elevated in
patients with meningitis in the HIV-uninfected group. The overall CFR was extremely high
(55%) in patients with meningitis and elevated compared to individuals with bacteremic
pneumonia. A study from Malawi, a country with a high population HIV prevalence, found
65% mortality in patients with meningitis compared to 20% for bacteremia[33]. In HIV-
infected individuals consumption of antibiotics in the two months preceding hospitalization
was predictive of elevated mortality; this likely reflected the severity of underlying HIV-related
illness, rather than infection with antibiotic non-susceptible organisms, because strain suscep-
tibility was not related to mortality on multivariable analysis. Residence in intermediate and
high poverty level provinces was also associated with increased mortality in HIV infected indi-
viduals. This is possibly related to different specimen-taking practices[34], where in less-
resourced provinces only the sickest individuals have specimens collected for culture; or due
to worse access to care or quality of care, although we do not have data to support this
hypothesis.
We found HIV-infected individuals to have an overall two times greater odds ratio of in-
hospital death compared to HIV-uninfected individuals. When stratified by syndrome, this
association was only seen in patients with meningitis (who experience six times increased odds
of death) but not in patients with bacteremic pneumonia. This difference in mortality associa-
tion by clinical syndrome is similar to what was found in a study of IPD in patients aged<15
years from South Africa in the pre-PCV era[35]. Published data on the association between
HIV infection and mortality vary, with some studies describing increased mortality in HIV-
infected individuals and others not finding this association[36–39]. These varying findings
could result from different populations studied including differing clinical syndromes included,
different proportions of patients receiving ART as well as limited statistical power to detect an
association in some studies.
Studies of the association between serotype and mortality have varied in the patient popula-
tions included, with some studies including only patients with bacteremic pneumonia and oth-
ers including all IPD[11, 29, 40]. When stratified by clinical syndrome, amongst patients with
bacteremic pneumococcal pneumonia, serotype 19F remained associated with increased mor-
tality, while no serotype was associated with increased mortality in patients with meningitis.
This suggests that the association between serotype and mortality may vary depending on the
clinical syndrome evaluated.
Other factors associated with increased mortality included increasing age group, which has
been described in several studies, most likely as a result of immunosenescence[41–44]. Notably,
the numbers of cases aged65 years was low, possibly as a result of reduced health seeking in
this age group as well as the relatively younger population than many high income countries
and the relatively low life expectancy in South Africa[45, 46]. In contrast to previous studies,
we did not find underlying illnesses (other than HIV) to be associated with increased in-hospi-
tal mortality. This could reflect poor diagnosis and documentation of underlying illness data in
our setting or reflect the relatively smaller contribution of underlying illness to in-hospital out-
come in this predominantly HIV-infected population[5–7].
Our study had some limitations. Only patients admitted to enhanced surveillance sites with
viable isolates were included. Patients at enhanced sites differed from those presenting to non-
enhanced sites with regard to a number of characteristics and this could potentially have intro-
duced bias. Because of the nature of laboratory-based surveillance, only patients who presented
to a healthcare facility and who had specimens taken could be included; these individuals may
not be fully representative, especially in the poorer provinces. We examined a large number of
serotypes individually, which may have reduced our power to detect significant associations,
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however we did have data on almost 4000 individuals and>1000 deaths. The ability to detect a
significant association with mortality for different serotypes could have been affected by avail-
able numbers of cases allowing insufficient power to detect statistically significant associations
in some cases. Some previous studies did not assess severity association for individual serotypes
but rather grouped them, limiting the ability to compare with our findings [40]. We elected not
to group serotypes for the mortality analysis as several different grouping have been used in the
literature, and all groupings are somewhat arbitrary and could introduce spurious associations
[11, 29, 40]. We included individuals aged15 years in our study, although a cut-off of18
years is more standard for adults. We did this because in South Africa 15 years is the age at
which patients are generally admitted to adult rather than pediatric wards in South Africa.
Importantly, individuals aged 15–17 years only made up 1% of the study population and study
conclusions remained unchanged on sensitivity analysis excluding this group of individuals.
CD4+ T cell count data was only available for 56% of HIV-infected patients and we therefore
did not include it in the analysis of factors associated with mortality; CD4+ T cell count, how-
ever, was not associated with serotype and it is therefore unlikely to be a confounder of the
association between serotype and mortality.
In conclusion, we have found that individual serotypes, included in PCV-13, were associated
with increasing mortality in the pre-PCV era in South Africa, even controlling for potential
confounding. HIV infection was also an important risk factor for death in our study, especially
among patients with meningitis and older individuals. Studies of the association of pneumo-
coccal serotype and mortality, following widespread PCV introduction and possible serotype
replacement, may be informative.
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